Parkinson’s disease (PD) is a neurodegenerative disorder that primarily affects dopamine-producing neurons in the substantia nigra, a part of the brain that plays a key role in reward and movement. This article aims to provide an in-depth overview of the pathophysiology, diagnosis, and management of PD.
The hallmark of PD is the progressive loss of dopaminergic neurons in the substantia nigra, leading to a decrease in striatal dopamine levels. This results in the characteristic motor symptoms of PD, including bradykinesia, resting tremor, rigidity, and postural instability. Non-motor symptoms such as cognitive impairment, depression, and autonomic dysfunction may also occur due to the involvement of non-dopaminergic pathways.
Diagnosis of PD is primarily clinical, based on the presence of characteristic motor symptoms and their response to dopaminergic therapy. Neuroimaging techniques such as dopamine transporter (DAT) SPECT can support the diagnosis, but are not routinely used due to their high cost and limited availability. There are no specific biomarkers for PD, which can make the diagnosis challenging, particularly in early stages of the disease.
Management of PD is symptomatic, aiming to improve quality of life by reducing motor and non-motor symptoms. Pharmacological therapy is the cornerstone of treatment, with levodopa being the most effective drug. Other medications include dopamine agonists, MAO-B inhibitors, and COMT inhibitors. Non-pharmacological interventions, such as physiotherapy and occupational therapy, also play a crucial role in managing the disease.
Parkinson’s disease is a complex neurodegenerative disorder with a multifaceted pathophysiology and clinical presentation. A thorough understanding of its pathophysiology, diagnosis, and management strategies is essential for healthcare professionals to provide optimal care for patients with PD.
1.
Tumor characteristics found to differ for melanomas in children, teens and young adults
2.
Unexplained CAR-T Death; Americans Spurn Sunscreen; Improving Diversity in Trials
3.
"A lot" of aspirin reduces the risk of ovarian cancer, regardless of genetic factors, according to the JAMA study.
4.
Approval in Endometrial Cancer Expanded; Masks at Cancer Centers; NPR Reporter Dies
5.
Is Lenalidomide Resistance in Myeloma Reversible with JAK Inhibition?
1.
Modern Oncology Unveiled with Treatment Innovations and Personalized Cancer Care
2.
Screening for Early Therapy-Related Cancer Susceptibility
3.
Unlocking the Potential of Bicalutamide 50 mg: A Revolutionary New Treatment for Prostate Cancer
4.
Skin-Sparing Mastectomy: Balancing Cancer Control with Cosmetic Results
5.
Reducing Modifiable Childhood Cancer Exposure Risks
1.
International Conference on Innovations in Critical Care for Oncology and Cardiology
2.
International Conference on Oncology, Cardiology and Critical Care Policy
3.
International Conference on Oncology, Cancer Prevention and Public Health
4.
International Conference on Cancer Nursing and Rehabilitation Strategies
5.
International Conference on Best Practices in Oncology, Cardiology and Critical Care
1.
Dacomitinib Case Presentation: Baseline Treatment and Current Status
2.
Targeting Oncologic Drivers with Dacomitinib: Further Discussion on Lung Cancer Treatment
3.
Should We Use DARA Up Front As First-Line Therapy in MM?
4.
Iron Deficiency Anemia: Ferric Maltol As a New Treatment Option- A New Perspective
5.
Importance of Cancer Screening and Early Detection
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation